NCT03525730View on ClinicalTrials.gov

LRAs United as a Novel Anti-HIV Strategy.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 18, 2018

Primary Completion Date

July 25, 2019

Study Completion Date

October 1, 2020

Conditions
HIV-1-infection
Interventions
DRUG

Valproic Acid

Valproic acid (enteric) 30mg/kg, divided over 2 doses per day, orally on day 1-14.

DRUG

Pyrimethamine

Pyrimethamine 200mg once daily (QD) orally on day 1 and 100mg on day 2-14.

Trial Locations (1)

3015 CN

Erasmus MC, Rotterdam

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER

NCT03525730 - LRAs United as a Novel Anti-HIV Strategy. | Biotech Hunter | Biotech Hunter